Christopher Noda1, Gregory A Williams1, Gretchen Foltz2, Hyun Kim3, Dominic E Sanford1, Chet W Hammill1, Ryan C Fields1. 1. Department of Surgery, Barnes-Jewish Hospital and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Radiology, Barnes-Jewish Hospital and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. 3. Department of Radiation Oncology, Barnes-Jewish Hospital and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Abstract
BACKGROUND AND OBJECTIVES: The liver is a frequent site of malignancy, both primary and metastatic. The treatment goal of patients with liver cancer may include transarterial radioembolization (TARE). There are limited reports on the safety of hepatectomy following TARE. Our study's purpose is to review patients who have received TARE followed by hepatectomy. METHODS: A retrospective study was performed on patients diagnosed with any liver cancer from 2013 to 2019 who underwent TARE followed by hepatectomy. Postoperative complications were prospectively collected. Descriptive statistics and the Kaplan-Meier test were used to assess survival outcomes. RESULTS: Twelve patients were treated with a TARE followed by a hepatectomy (nine with ≥4 segments resected). Diagnoses included: six HCC, four cholangiocarcinoma, one metastatic neuroendocrine tumor, and one metastatic colorectal cancer. There were no 90-day post-hepatectomy mortalities and the overall morbidity was 66% (16% severe ≥MAGS 3). Hepatectomy-specific complications after hepatectomy included two (16%) bile leaks and no post-hepatectomy liver failures. The median recurrence free survival was 26 months. Overall survival at 1-year was 78% and at 3 years was 47%. CONCLUSIONS: Our results support the safety of hepatectomy in select patients after TARE. Additional comparison to patients who receive hepatectomy as a first-line treatment for liver cancers should be investigated.
BACKGROUND AND OBJECTIVES: The liver is a frequent site of malignancy, both primary and metastatic. The treatment goal of patients with liver cancer may include transarterial radioembolization (TARE). There are limited reports on the safety of hepatectomy following TARE. Our study's purpose is to review patients who have received TARE followed by hepatectomy. METHODS: A retrospective study was performed on patients diagnosed with any liver cancer from 2013 to 2019 who underwent TARE followed by hepatectomy. Postoperative complications were prospectively collected. Descriptive statistics and the Kaplan-Meier test were used to assess survival outcomes. RESULTS: Twelve patients were treated with a TARE followed by a hepatectomy (nine with ≥4 segments resected). Diagnoses included: six HCC, four cholangiocarcinoma, one metastatic neuroendocrine tumor, and one metastatic colorectal cancer. There were no 90-day post-hepatectomy mortalities and the overall morbidity was 66% (16% severe ≥MAGS 3). Hepatectomy-specific complications after hepatectomy included two (16%) bile leaks and no post-hepatectomy liver failures. The median recurrence free survival was 26 months. Overall survival at 1-year was 78% and at 3 years was 47%. CONCLUSIONS: Our results support the safety of hepatectomy in select patients after TARE. Additional comparison to patients who receive hepatectomy as a first-line treatment for liver cancers should be investigated.
Authors: Jehan L Shah; Ivan R Zendejas-Ruiz; Linday M Thornton; Brian S Geller; Joseph R Grajo; Amy Collinsworth; Thomas J George; Beau Toskich Journal: J Gastrointest Oncol Date: 2017-06
Authors: M Iñarrairaegui; F Pardo; J I Bilbao; F Rotellar; A Benito; D D'Avola; J I Herrero; M Rodriguez; P Martí; G Zozaya; I Dominguez; J Quiroga; B Sangro Journal: Eur J Surg Oncol Date: 2012-03-21 Impact factor: 4.424
Authors: M Rayar; L Sulpice; J Edeline; E Garin; G B Levi Sandri; B Meunier; E Boucher; K Boudjema Journal: Ann Surg Oncol Date: 2015-01-27 Impact factor: 5.344
Authors: Jessica P Simons; Sing Chau Ng; Joshua S Hill; Shimul A Shah; Zheng Zhou; Jennifer F Tseng Journal: Cancer Date: 2010-04-01 Impact factor: 6.860
Authors: David G Brauer; Matthew S Strand; Dominic E Sanford; Vladimir M Kushnir; Kian-Huat Lim; Daniel K Mullady; Benjamin R Tan; Andrea Wang-Gillam; Ashley E Morton; Marianna B Ruzinova; Parag J Parikh; Vamsi R Narra; Kathryn J Fowler; Majella B Doyle; William C Chapman; Steven S Strasberg; William G Hawkins; Ryan C Fields Journal: HPB (Oxford) Date: 2016-12-01 Impact factor: 3.647
Authors: Ryan Whitney; Cliff Tatum; Mike Hahl; Susan Ellis; Charles R Scoggins; Kelly McMasters; Robert C G Martin Journal: J Surg Res Date: 2009-06-12 Impact factor: 2.192
Authors: Samdeep Mouli; Khairuddin Memon; Talia Baker; Al B Benson; Mary F Mulcahy; Ramona Gupta; Robert K Ryu; Riad Salem; Robert J Lewandowski Journal: J Vasc Interv Radiol Date: 2013-04-19 Impact factor: 3.464
Authors: Sebastian Mafeld; Peter Littler; Hannah Hayhurst; Derek Manas; Ralph Jackson; John Moir; Jeremy French Journal: J Gastrointest Cancer Date: 2020-03
Authors: Daniel Aliseda; Pablo Martí-Cruchaga; Gabriel Zozaya; Alberto Benito; Luis Lopez-Olaondo; Macarena Rodríguez-Fraile; José I Bilbao; Francisco Hidalgo; Mercedes Iñarrairaegui; Rubén Ciria; Fernando Pardo; Bruno Sangro; Fernando Rotellar Journal: Langenbecks Arch Surg Date: 2022-02-28 Impact factor: 2.895